Obesity News

PHILADELPHIA — In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg was superior to placebo for reducing cardiovascular risk in adults with preexisting heart disease and overweight or obesity but without diabetes.

Weight loss presented as a positive opportunity by physicians was associated with greater uptake of treatment and weight loss, a study published in Annals of Internal Medicine found.

WASHINGTON —Pediatric obesity and guidelines on how to manage it were the focus of several symposiums at the AAP National Conference & Exhibition.

The FDA approved the injectable GIP/GLP-1 dual incretin-based agonist tirzepatide for chronic weight management among adults with obesity, according to a press release.

The recommendation that people living with diabetes should avoid carbohydrates is misguided, according to a speaker at the Lifestyle Medicine Conference.

DENVER — Integrating lifestyle coaching in a primary care model was feasible and significantly improved several dietary measures and health outcomes, according to data presented at the Lifestyle Medicine Conference.

Adults with type 2 diabetes and obesity achieved greater weight loss with time-restricted eating at 6 months than with calorie restriction or continuing usual eating habits, according to study data.

DENVER — Lifestyle medicine is a central component of obesity treatment, including for adults who receive anti-obesity medications or undergo bariatric surgery, according to three speakers at the Lifestyle Medicine Conference.

DENVER — A lifestyle medicine approach can address gaps in pediatric obesity care, according to presenters at the annual American College of Lifestyle Medicine’s annual meeting.

Obesity is one of the most common chronic preventable comorbidities affecting adults and children in the United States.